2 completed, 1 not yet recruiting, 1 recruiting. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
Follow Recurrent Rhabdomyosarcoma: new trials by email Literature Review of Recurrent Rhabdomyosarcoma trials Research Report on Recurrent Rhabdomyosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat Archive Sample Retrieval, Biospecimen Collection, pH Low Insertion Peptide-exatecan Conjugate CBX-12 - Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 79 | 2027-05-07 | 2026-09-22 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Adavosertib, Irinotecan Hydrochloride - Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 76 | 2014-03-28 | 2023-09-26 |
Rhabdomyosarcoma (4) · Neuroblastoma (3) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Osteosarcoma (2) · Sarcoma, Ewing (2) · Central Nervous System Neoplasms (1) · Hepatoblastoma (1) · Hodgkin Disease (1) · Lymphoma, Non-Hodgkin (1) · Medulloblastoma (1) · Melanoma (1) · Neoplasms (1) · Neuroectodermal Tumors, Primitive (1) · Pinealoma (1) · Rhabdoid Tumor (1)
Myosarcoma (4) · Neoplasms by Histologic Type (4) · Neoplasms, Connective and Soft Tissue (4) · Neoplasms, Muscle Tissue (4) · Neoplasms (3) · Neoplasms by Site (3) · Neoplasms, Bone Tissue (3) · Neoplasms, Connective Tissue (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3) · Neoplasms, Neuroepithelial (3) · Neuroectodermal Tumors (3) · Sarcoma (3) · Neuroectodermal Tumors, Primitive (2)
CTLA-4 Antigen (1) · Ipilimumab (1) · Irinotecan (1) · Nivolumab (1) · Specimen Handling (1) · Temozolomide (1) · adavosertib (1) · irinotecan sucrosofate (1) · talazoparib (1)
National Cancer Institute (NCI) (2) · Children's Oncology Group (1) · St. Jude Children's Research Hospital (1)
Canada (3) · United States (3)
Crystal L Mackall (1) · Juan C Vasquez (1) · Kristina A Cole (1) · Sara Federico, MD (1)
UM1CA097452 (2), UM1CA228823 (1)